Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Aldeyra Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Aldeyra Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Aldeyra Therapeutics's earnings are expected to grow significantly at over 20% yearly.
Unable to determine if Aldeyra Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Aldeyra Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Aldeyra Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Aldeyra Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Aldeyra Therapeutics has no long term commitments.
This treemap shows a more detailed breakdown of
Aldeyra Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Aldeyra Therapeutics has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Todd C. Brady, M.D., Ph.D., has been the Chief Executive Officer and President of Aldeyra Therapeutics, Inc. since January 2012. Dr. Brady is a Co-Founder of Phenome Sciences and serves as its Chief Executive Officer. He serves as a Senior Advisor at Solidus Investment Co., Ltd. He served as Principal Financial and Accounting Officer of Aldeyra Therapeutics, Inc. He was an Entrepreneur-In-Residence at Domain Associates, L.L.C since 2013. He joined Domain Associates in 2004 and served as Principal from 2004 to 2013. He served as an Executive Vice President of Strategic Development and Planning at Xanthus Pharmaceuticals. Dr. Brady served as the Head of Business Development and Medical Director at Aderis Pharmaceuticals. While at Xanthus and Aderis, he was a Medical Consultant on numerous pre-clinical programs and eleven clinical programs in Phases I through IV. He was an Associate of CB Health Ventures, L.L.C. and CB Healthcare II, LP. He was a Senior Associate at CB Health Ventures in Boston. He has been a Director of Spring Bank Pharmaceuticals, Inc. since July 28, 2016. Dr. Brady has been an Independent Director of Aldeyra Therapeutics, Inc. since 2005, Southeast BIO since November 2006 and Cantex Pharmaceuticals, Inc., since August 2006. He serves as a Director at Aldexa Pharmasceuticals, Asmacure Ltée, Neuron Systems, Inc., NovaDigm Therapeutics, Inc., Sebacia and CardioPolymers, Inc. He serves as Board Observer status at Orqis Medical, Regado Biosciences, Ruxton Pharmaceuticals, IntegenX Inc.,Cortria Corporation, Microchip Biotechnologies and Meritage Pharma, Inc. He served as a Director of Oncobiologics, Inc. from September 2014 to October 31, 2017. He served as Board Observer at Celator Pharmaceuticals, Inc. and Esperion Therapeutics, Inc. Dr. Brady has been a Director of Evoke Pharma, Inc., since June 2007. He served as an Board Observer at Helixis, Inc and Carticept Medical, Inc. He is on the grant review Board for the New Jersey Commission on Science and Technology, the venture capital Advisor to the New Jersey Biotechnology Council Board of Trustees, a Member of the Duke University Graduate School Board of Visitors, an Advisor to the Translational Science Institute at Wake Forest University and the University of Virgina Coulter Translational Research Advisory Board. He received an M.D. from Duke University Medical School in 1999 and a Ph.D. in Pathology and Integrated Toxicology from the Duke University Graduate School in 1998, while working on the pre-clinical development of catalytic anti-inflammatory compounds. He also received an A.B. in Philosophy and Psychology from Dartmouth College in 1993.
Todd's compensation has increased whilst company is loss making.
Todd's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Aldeyra Therapeutics management team is less than 2 years, this suggests a new team.
CEO, President & Director
Chief Medical Officer
Chief Financial Officer
Senior Vice President of Technical Operations
Senior Vice President of Regulatory Affairs
Chief Commercial Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Aldeyra Therapeutics board of directors is about average.
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company’s lead product candidate is reproxalap, an ophthalmic solution, which is in Phase IIb clinical trial for the treatment of dry eye diseases, as well as Phase III clinical trial for the treatment of allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson syndrome. Its portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative inflammatory diseases; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, as well as ADX-103 for the treatment of retinal diseases. In addition, the company develops ADX-2191, an intravitreal dihydrofolate reductase inhibitor for the prevention of proliferative vitreoretinopathy, a sight-threatening retinal disease; and ADX-1615, which inhibits Hsp90 for the treatment of various inflammatory diseases. Aldeyra Therapeutics, Inc. has a partnership with Janssen, a Johnson & Johnson company to develop RASP for systemic inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.